<DOC>
	<DOCNO>NCT02276482</DOCNO>
	<brief_summary>The purpose study compare safety intravenous ( IV ) and/or oral 6-day 200 mg tedizolid phosphate 10-day comparator participant 12 &lt; 18 year cSSTI .</brief_summary>
	<brief_title>Study Tedizolid Phosphate Adolescents With Complicated Skin Soft Tissue Infection ( cSSTI ) ( MK-1986-012 )</brief_title>
	<detailed_description>A randomized , single-blind , multicenter , Phase 3 study IV and/or oral tedizolid phosphate 200 mg per day 6 day compare IV and/or oral Comparator 10 day treatment cSSTI , also know acute bacterial skin skin structure infection , participant 12 &lt; 18 year . cSSTI include major cutaneous abscess , cellulitis/erysipelas , wound infection .</detailed_description>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Skin Diseases , Bacterial</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Males females 12 year &lt; 18 year Adequate venous access IV administration study drug least 24 hour ( participant receive IV medication ) collection protocolspecified blood sample Local symptom must start within 7 day Study Day 1 cSSTI meeting least 1 clinical syndrome definition . Suspected documented Grampositive infection baseline Gram stain culture . Parent/legally authorize representative ( LAR ) able give inform consent willing able comply require study procedure . Assent also require child Investigator 's judgment capable understanding nature study Uncomplicated minor skin skin structure infection pustule , folliculitis , furuncle , minor abscess ( small volume suppuration surround cellulitis/erysipelas ) , impetiginous lesion , superficial limited cellulitis/erysipelas , minor wound associate foreign body reaction ( eg , stitch abscess ) Known bacteremia , severe sepsis septic shock Recent history opportunistic infection underlie cause infection still active ( eg , leukemia , transplant , acquire immunodeficiency syndrome ) Hypersensitivity tedizolid phosphate component formulation Hypersensitivity comparator drug ; hypersensitivity comparator drug preclude participation alternative comparator use For participant wound infection : history hypersensitivity ceftazidime , aztreonam , component aztreonam formulation , aztreonam adjunctive therapy require ; history hypersensitivity metronidazole component formulation , metronidazole adjunctive therapy require Needs oral administration methotrexate , topotecan , irinotecan rosuvastatin , administration oral study drug .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>